Extracorporeal Endotoxin Removal
PMX is a Polymyxin B extracorporeal direct hemoperfusion adsorption column which is highly effective in removing endotoxin in the bloodstream.
- Clinically available since 1995*
- More than 340,000 treatments performed worldwide
- Reproducible clinical benefits
- As of 2019, more than 200 scientific papers and peer reviewed articles available
*PMX has been approved and marketed by Toray Industries in Europe and Japan since 1994 and 2002 respectively, and has been used safely on more than 340,000 patients worldwide.
PMX is available in Canada where Spectral holds the exclusive rights for its distribution. In the United States, the PMX cartridge is undergoing a clinical trial under an IDE with the FDA. The Tigris trial (ClinicalTrials.gov Identifier: NCT03901807) is a follow on study to the EUPHRATES trial. The Tigris trial is a randomized study, controlled study of use of the PMX cartridge versus standard of care for patients with septic shock and endotoxemia (measured as EA level of ≥ 0.60 to 0.90)
Recent data suggests that the best patients for PMX therapy have the following characteristics:
• Septic shock requiring continuous vasopressor support
• EAA ≥0.60 and <0.90
• Multiple Organ Dysfunction (MODS>9)
The graphic describes the decision making process that should be followed to prescribe PMX hemoperfusion therapy.
Additionally, patients who received PMX therapy had a greater increase in mean arterial pressure as well as a decreased requirement for vasopressors.